Sfoglia per Autore
Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients
2016-01-01 Marascio, Nadia; Grazia, Pavia1; Alessio, Strazzulla; Tim, Dierckx; Lize, Cuypers; Bram, Vrancken; Giorgio Settimo Barreca, ; Teresa, Mirante; Malanga, D; Duarte Mendes Oliveira, ; Anne-Mieke, Vandamme; Torti, C; Liberto, M; Focà, A; The Sinergie-Umg Study, Group.
Six years genotype distribution of Human Papillomavirus in Calabria Region, Southern Italy: a retrospective study.
2017-01-01 Galati, L; Peronace, C; Fiorillo, Mt; Masciari, R; Giraldi, C; Nisticò, S; Minchella, P; Maiolo, V; Barreca, Gs; Marascio, N; Lamberti, Ag; Giancotti, A; Lepore, Mg; Greco, F; Mauro, Mv; Borelli, A; Bocchiaro, Gl; Surace, G; Liberto, M; Focà, A.
SOLUBLE CD14 SUBTYPE - A NEW BIOMARKER IN PREDICTING OUTCOME OF CRITICALLY ILL SEPTIC PATIENTS: AN OBSERVATIONAL PROSPECTIVE STUDY.
2017-01-01 Matera, G; Quirino, A; Peronace, C; Settembre, P; Marano, V; Loria, Mt; Marascio, N; Galati, L; Barreca, Gs; Giancotti, A; Amantea, B; Liberto, Mc; Focà, A
Soluble CD14 Subtype-A New Biomarker in Predicting the Outcome of Critically Ill Septic Patients.
2017-01-01 Matera, G; Peronace, C; Settembre, P; Marano, V; Loria, Mt; Marascio, N; Galati, L; Barreca, Gs; Giancotti, A; Amantea, B; Liberto, M; Focà, A.; Quirino, A
Resistance-associated and fitness-associated substitutions on NS3, NS5A and NS5B genes in real-life HCV positive patient failed to 3D therapy.
2017-01-01 Marascio, N; Di Salvo, S; Pavia, G; Zicca, E; Marano, V; Barreca, Gs; Fabiani, F; De Siena, M; Giancotti, F; Gravina, T; Torti, C; Liberto, Mc; Focà, A.
Data presentation HCV virology
2017-01-01 Marascio, N
31st International papillomavirus conference Cape Town, 28 Febbraio - 4 Marzo 2017.
2017-01-01 Focà, A; Galati, L; Peronace, C; Fiorillo, Mt; Masciari, R; Giraldi, C; Nisticò, S; Minchella, P; Maiolo, V; Barreca, Gs; Marascio, N; Lamberti, Ag; Giancotti, A; Lepore, Mg; Greco, F; Mauro, Mv; Borelli, A; Lo Bocchiaro, G; Surace, G; Liberto, Mc.
Resistance-associated and fitness-associated substitutions on NS3, NS5A and NS5B genes in real-life HCV positive patient failed to 3D therapy.
2017-01-01 Marascio, N; Di Salvo, S; Pavia, G; Zicca, E; Marano, V; Barreca, Gs; Fabiani, F; De Siena, M; Giancotti, F; Gravina, T; Torti, C; Liberto, Mc; Focà, A. 1.
Resistance-associated substitutions among HCV1b virus populations in patients who failed DAA based regimens.
2017-01-01 Pavia, G; Marascio, N; Dierckx, T; Cuypers, L; Vrancken, B; Pisani, V; Barreca, Gs; Mirante, T; Malanga, D; Viglietto, G; Vandamme, Am; Torti, C; Liberto, Mc; Focà, A.
Update on HPV epidemiology in Calabria Region, Southern Italy.
2017-01-01 Galati, L; Focà, A; Peronace, C; Fiorillo, Mt; Masciari, R; Giraldi, C; Nisticò, S; Minchella, P; Maiolo, V; Barreca, Gs; Marascio, N; Lamberti, Ag; Giancotti, A; Lepore, Mg; Greco, F; Mauro, Mv; Borelli, A; Lo Bocchiaro, G; Surace, G; Liberto, Mc.
Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
2017-01-01 Cuypers, L; Vrancken, B; Fabeni, L; Marascio, N; Cento, V; Di Maio, Vc; Aragri, M; Pineda-Peña, Ac; Schrooten, Y; Van Laethem, K; Balog, D; Focà, A; Torti, C; Nevens, F; Perno, Cf; Vandamme, Am; Ceccherini-Silberstein, F
Evolution of glomerular filtration rates an neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals
2018-01-01 Strazzulla, A; Coppolino, G; Barreca, Gs; Gentile, I; Rivoli, L; Postorino, Mc; Mazzitelli, M; Greco, G; Costa, C; Pisani, V; Marascio, N; Simeoni, M; Foca', A; Fuiano, G; Foti, D; Gulletta, E; Torti, C; Postorino, Mc; Mazzitelli, M; Greco, G; Costa, C; Pisani, V; Marascio, N; Torti, C; Fuiano, G
Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals.
2018-01-01 Strazzulla, A; Coppolino, G; Barreca, Gs; Gentile, I; Rivoli, L; Postorino, Mc; Mazzitelli, M; Greco, G; Costa, C; Pisani, V; Marascio, N; Simeoni, M; Focà, A; Fuiano, G; Foti, D; Gulletta, E; Torti, C.
Real-world efficacy of HCV subtype 4d treatments: clinical cases
2018-01-01 Marascio, N; Pavia, G; Giancotti, F; Di Salvo, S; Reale, M; Barreca, Gs; De Siena, M; Gravina, T; Casalinuovo, F; Torti, C; Liberto, Mc; Focà, A.
Analysis of dominant viral populations isolated from two pediatric patients infected by HCV genotype 4.
2018-01-01 Marascio, N; Mazzitelli, M; Pavia, G; Costa, C; Greco, G; Postorino, Mc; Barreca, Gs; Pisani, V; Casalinuovo, F; Liberto, Mc; Torti, C; Focà, A.
HCV genotipo 3: prevalenza nella nuova era del trattamento con DAA.
2018-01-01 Marascio, N; Pavia, G; Barreca, Gs; Reale, M; Scarlata, Ggm; Matera, G; Torti, C; Liberto, Mc; Focà, A.
Prevalenza di HCV3 ed HCV4 nella nuova era degli antivirali ad azione diretta (DAA)
2018-01-01 Marascio, N; Reale, M; Pavia, G; Barreca, Gs; Lamberti, Ag; Costa, C; Pisani, V; Trecarichi, E; Mazzitelli, M; Serapide, F; Greco, G; Matera, G; Liberto, Mc; Torti, C; Focà, A.
Utility of Molecular Identification and Quantitation of Bartonella Species with Species-Specific Real-Time PCR for Monitoring Treatment Response: A Case Series.
2018-01-01 Mazzitelli, M; Lamberti, Ag; Marascio, N; Barreca, Gs; Costa, C; Pisani, V; Strazzulla, A; Greco, G; Focà, A; Torti, C; Quirino, A; Liberto, M
Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
2018-01-01 Mazzitelli, M; Sabatino, J; D'Ascoli, Gl; Costa, C; Pisani, V; Raffetti, E; Strazzulla, A; Foca', A; Liberto, Mc; Indolfi, C; THE CARDIAC STUDY GROUP (BARRECA, Gs; Costanzo, Fs; Foti, D; Fuiano, G; Greco, G; Serapide, F; Gulletta, E; Marascio, N; Postorino, Mc; Simeoni, Ma; Foca', A; Liberto, Mc; Giancotti, A); De Rosa, S; Torti, C
Real-life 3D therapy failure: analysis of NS5A 93H RAS plus 108K polymorphism in complex with ombitasvir by molecular modeling
2018-01-01 Marascio, N; Pavia, G; Romeo, I; Talarico, C; Di Salvo, S; Reale, M; Marano, V; Settimo Barreca, G; Fabiani, F; De Siena, M; Giancotti, F; Gravina, T; Alcaro, S; Artese, A; Focà, A; Perrotti, N; Torti, C; Liberto, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients | 1-gen-2016 | Marascio, Nadia; Grazia, Pavia1; Alessio, Strazzulla; Tim, Dierckx; Lize, Cuypers; Bram, Vrancken; Giorgio Settimo Barreca, ; Teresa, Mirante; Malanga, D; Duarte Mendes Oliveira, ; Anne-Mieke, Vandamme; Torti, C; Liberto, M; Focà, A; The Sinergie-Umg Study, Group. | |
| Six years genotype distribution of Human Papillomavirus in Calabria Region, Southern Italy: a retrospective study. | 1-gen-2017 | Galati, L; Peronace, C; Fiorillo, Mt; Masciari, R; Giraldi, C; Nisticò, S; Minchella, P; Maiolo, V; Barreca, Gs; Marascio, N; Lamberti, Ag; Giancotti, A; Lepore, Mg; Greco, F; Mauro, Mv; Borelli, A; Bocchiaro, Gl; Surace, G; Liberto, M; Focà, A. | |
| SOLUBLE CD14 SUBTYPE - A NEW BIOMARKER IN PREDICTING OUTCOME OF CRITICALLY ILL SEPTIC PATIENTS: AN OBSERVATIONAL PROSPECTIVE STUDY. | 1-gen-2017 | Matera, G; Quirino, A; Peronace, C; Settembre, P; Marano, V; Loria, Mt; Marascio, N; Galati, L; Barreca, Gs; Giancotti, A; Amantea, B; Liberto, Mc; Focà, A | |
| Soluble CD14 Subtype-A New Biomarker in Predicting the Outcome of Critically Ill Septic Patients. | 1-gen-2017 | Matera, G; Peronace, C; Settembre, P; Marano, V; Loria, Mt; Marascio, N; Galati, L; Barreca, Gs; Giancotti, A; Amantea, B; Liberto, M; Focà, A.; Quirino, A | |
| Resistance-associated and fitness-associated substitutions on NS3, NS5A and NS5B genes in real-life HCV positive patient failed to 3D therapy. | 1-gen-2017 | Marascio, N; Di Salvo, S; Pavia, G; Zicca, E; Marano, V; Barreca, Gs; Fabiani, F; De Siena, M; Giancotti, F; Gravina, T; Torti, C; Liberto, Mc; Focà, A. | |
| Data presentation HCV virology | 1-gen-2017 | Marascio, N | |
| 31st International papillomavirus conference Cape Town, 28 Febbraio - 4 Marzo 2017. | 1-gen-2017 | Focà, A; Galati, L; Peronace, C; Fiorillo, Mt; Masciari, R; Giraldi, C; Nisticò, S; Minchella, P; Maiolo, V; Barreca, Gs; Marascio, N; Lamberti, Ag; Giancotti, A; Lepore, Mg; Greco, F; Mauro, Mv; Borelli, A; Lo Bocchiaro, G; Surace, G; Liberto, Mc. | |
| Resistance-associated and fitness-associated substitutions on NS3, NS5A and NS5B genes in real-life HCV positive patient failed to 3D therapy. | 1-gen-2017 | Marascio, N; Di Salvo, S; Pavia, G; Zicca, E; Marano, V; Barreca, Gs; Fabiani, F; De Siena, M; Giancotti, F; Gravina, T; Torti, C; Liberto, Mc; Focà, A. 1. | |
| Resistance-associated substitutions among HCV1b virus populations in patients who failed DAA based regimens. | 1-gen-2017 | Pavia, G; Marascio, N; Dierckx, T; Cuypers, L; Vrancken, B; Pisani, V; Barreca, Gs; Mirante, T; Malanga, D; Viglietto, G; Vandamme, Am; Torti, C; Liberto, Mc; Focà, A. | |
| Update on HPV epidemiology in Calabria Region, Southern Italy. | 1-gen-2017 | Galati, L; Focà, A; Peronace, C; Fiorillo, Mt; Masciari, R; Giraldi, C; Nisticò, S; Minchella, P; Maiolo, V; Barreca, Gs; Marascio, N; Lamberti, Ag; Giancotti, A; Lepore, Mg; Greco, F; Mauro, Mv; Borelli, A; Lo Bocchiaro, G; Surace, G; Liberto, Mc. | |
| Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy | 1-gen-2017 | Cuypers, L; Vrancken, B; Fabeni, L; Marascio, N; Cento, V; Di Maio, Vc; Aragri, M; Pineda-Peña, Ac; Schrooten, Y; Van Laethem, K; Balog, D; Focà, A; Torti, C; Nevens, F; Perno, Cf; Vandamme, Am; Ceccherini-Silberstein, F | |
| Evolution of glomerular filtration rates an neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals | 1-gen-2018 | Strazzulla, A; Coppolino, G; Barreca, Gs; Gentile, I; Rivoli, L; Postorino, Mc; Mazzitelli, M; Greco, G; Costa, C; Pisani, V; Marascio, N; Simeoni, M; Foca', A; Fuiano, G; Foti, D; Gulletta, E; Torti, C; Postorino, Mc; Mazzitelli, M; Greco, G; Costa, C; Pisani, V; Marascio, N; Torti, C; Fuiano, G | |
| Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. | 1-gen-2018 | Strazzulla, A; Coppolino, G; Barreca, Gs; Gentile, I; Rivoli, L; Postorino, Mc; Mazzitelli, M; Greco, G; Costa, C; Pisani, V; Marascio, N; Simeoni, M; Focà, A; Fuiano, G; Foti, D; Gulletta, E; Torti, C. | |
| Real-world efficacy of HCV subtype 4d treatments: clinical cases | 1-gen-2018 | Marascio, N; Pavia, G; Giancotti, F; Di Salvo, S; Reale, M; Barreca, Gs; De Siena, M; Gravina, T; Casalinuovo, F; Torti, C; Liberto, Mc; Focà, A. | |
| Analysis of dominant viral populations isolated from two pediatric patients infected by HCV genotype 4. | 1-gen-2018 | Marascio, N; Mazzitelli, M; Pavia, G; Costa, C; Greco, G; Postorino, Mc; Barreca, Gs; Pisani, V; Casalinuovo, F; Liberto, Mc; Torti, C; Focà, A. | |
| HCV genotipo 3: prevalenza nella nuova era del trattamento con DAA. | 1-gen-2018 | Marascio, N; Pavia, G; Barreca, Gs; Reale, M; Scarlata, Ggm; Matera, G; Torti, C; Liberto, Mc; Focà, A. | |
| Prevalenza di HCV3 ed HCV4 nella nuova era degli antivirali ad azione diretta (DAA) | 1-gen-2018 | Marascio, N; Reale, M; Pavia, G; Barreca, Gs; Lamberti, Ag; Costa, C; Pisani, V; Trecarichi, E; Mazzitelli, M; Serapide, F; Greco, G; Matera, G; Liberto, Mc; Torti, C; Focà, A. | |
| Utility of Molecular Identification and Quantitation of Bartonella Species with Species-Specific Real-Time PCR for Monitoring Treatment Response: A Case Series. | 1-gen-2018 | Mazzitelli, M; Lamberti, Ag; Marascio, N; Barreca, Gs; Costa, C; Pisani, V; Strazzulla, A; Greco, G; Focà, A; Torti, C; Quirino, A; Liberto, M | |
| Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients | 1-gen-2018 | Mazzitelli, M; Sabatino, J; D'Ascoli, Gl; Costa, C; Pisani, V; Raffetti, E; Strazzulla, A; Foca', A; Liberto, Mc; Indolfi, C; THE CARDIAC STUDY GROUP (BARRECA, Gs; Costanzo, Fs; Foti, D; Fuiano, G; Greco, G; Serapide, F; Gulletta, E; Marascio, N; Postorino, Mc; Simeoni, Ma; Foca', A; Liberto, Mc; Giancotti, A); De Rosa, S; Torti, C | |
| Real-life 3D therapy failure: analysis of NS5A 93H RAS plus 108K polymorphism in complex with ombitasvir by molecular modeling | 1-gen-2018 | Marascio, N; Pavia, G; Romeo, I; Talarico, C; Di Salvo, S; Reale, M; Marano, V; Settimo Barreca, G; Fabiani, F; De Siena, M; Giancotti, F; Gravina, T; Alcaro, S; Artese, A; Focà, A; Perrotti, N; Torti, C; Liberto, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile